{"title":"遗传性代谢紊乱:表现、临床类型、实验室诊断和遗传标记。","authors":"Aamir Ijaz, Seyyedha Abbas, Maria Shabbir, Yasmin Badshah, Fizzah Abid, Tayyaba Afsar, Suhail Razak","doi":"10.1186/s13023-025-03979-8","DOIUrl":null,"url":null,"abstract":"<p><p>Inherited metabolic disorders (IMDs) are classified under rare genetic diseases almost always presenting in newborn and infants. IMDs are classified according to the clinical presentation, diagnosis and prognosis. Several factors are involved in the IMDs pathogenesis. Moreover, almost all IMDs follows the autosomal recessive inheritance pattern. At the basis of these diseases lie genetic mutations that affect metabolic pathways. The diagnosis is made by clinical manifestations in addition to biochemical tests and genetic analysis. Due to the different metabolic pathways involved, the multi-omics approaches can significantly increase diagnosis sensitivity. Early identification and diagnosis of IMD are critical to avoid death or neurological defects. In developing countries, lack of timely diagnosis exists mostly due to socioeconomic factors and unawareness. Research needs to be conducted to find better options for the treatment of IMDs. Understanding the molecular mechanisms of IMDs would be helpful in understanding the challenges that exist for the treatment of IMDs. This review aims to provide understanding regarding the pathogenesis of IMDs. Also, to highlight the challenges that exist in the effective treatment and diagnosis of IMDs.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":"20 1","pages":"422"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341273/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inherited metabolic disorders: presentation, clinical types, laboratory diagnosis and genetic markers.\",\"authors\":\"Aamir Ijaz, Seyyedha Abbas, Maria Shabbir, Yasmin Badshah, Fizzah Abid, Tayyaba Afsar, Suhail Razak\",\"doi\":\"10.1186/s13023-025-03979-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inherited metabolic disorders (IMDs) are classified under rare genetic diseases almost always presenting in newborn and infants. IMDs are classified according to the clinical presentation, diagnosis and prognosis. Several factors are involved in the IMDs pathogenesis. Moreover, almost all IMDs follows the autosomal recessive inheritance pattern. At the basis of these diseases lie genetic mutations that affect metabolic pathways. The diagnosis is made by clinical manifestations in addition to biochemical tests and genetic analysis. Due to the different metabolic pathways involved, the multi-omics approaches can significantly increase diagnosis sensitivity. Early identification and diagnosis of IMD are critical to avoid death or neurological defects. In developing countries, lack of timely diagnosis exists mostly due to socioeconomic factors and unawareness. Research needs to be conducted to find better options for the treatment of IMDs. Understanding the molecular mechanisms of IMDs would be helpful in understanding the challenges that exist for the treatment of IMDs. This review aims to provide understanding regarding the pathogenesis of IMDs. Also, to highlight the challenges that exist in the effective treatment and diagnosis of IMDs.</p>\",\"PeriodicalId\":19651,\"journal\":{\"name\":\"Orphanet Journal of Rare Diseases\",\"volume\":\"20 1\",\"pages\":\"422\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341273/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orphanet Journal of Rare Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13023-025-03979-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-025-03979-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
Inherited metabolic disorders (IMDs) are classified under rare genetic diseases almost always presenting in newborn and infants. IMDs are classified according to the clinical presentation, diagnosis and prognosis. Several factors are involved in the IMDs pathogenesis. Moreover, almost all IMDs follows the autosomal recessive inheritance pattern. At the basis of these diseases lie genetic mutations that affect metabolic pathways. The diagnosis is made by clinical manifestations in addition to biochemical tests and genetic analysis. Due to the different metabolic pathways involved, the multi-omics approaches can significantly increase diagnosis sensitivity. Early identification and diagnosis of IMD are critical to avoid death or neurological defects. In developing countries, lack of timely diagnosis exists mostly due to socioeconomic factors and unawareness. Research needs to be conducted to find better options for the treatment of IMDs. Understanding the molecular mechanisms of IMDs would be helpful in understanding the challenges that exist for the treatment of IMDs. This review aims to provide understanding regarding the pathogenesis of IMDs. Also, to highlight the challenges that exist in the effective treatment and diagnosis of IMDs.
期刊介绍:
Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.